Related Experiment Video
Updated: Dec 18, 2025
07:17
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
Published on: September 24, 2020
11.9K
Mir34a constrains pancreatic carcinogenesis.
Ana Hidalgo-Sastre1, Clara Lubeseder-Martellato1, Thomas Engleitner2
1Klinik und Poliklinik für Innere Medizin II, Technical University of Munich, Munich, Germany.
Scientific Reports
|June 17, 2020
Summary
MicroRNA 34a (Mir34a) loss accelerates pancreatic ductal adenocarcinoma (PDAC) development in mice. This suggests Mir34a restrains PDAC by modulating the immune microenvironment, offering a potential therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Over 70 microRNAs are dysregulated in pancreatic ductal adenocarcinoma (PDAC), impacting key cancer processes.
- Key genetic drivers of PDAC include Kras mutations and Tp53 tumor suppressor loss.
- MicroRNA 34a (Mir34a), a target of Tp53, is epigenetically silenced in PDAC, correlating with poor prognosis.
Purpose of the Study:
- To investigate the role of Mir34a as a suppressor of PDAC formation.
- To determine if Mir34a deficiency exacerbates PDAC development in a relevant preclinical model.
Main Methods:
- Generation of a pancreas-specific PDAC mouse model with Mir34a loss (KrasG12D; Mir34aΔ/Δ).
- Histological analysis and comparison with control KrasG12D mice.
- Assessment of pro-inflammatory cytokine (TNFA, IL6) expression and immune cell infiltration.
Main Results:
- Mice lacking Mir34a exhibited accelerated formation of pre-neoplastic lesions and faster PDAC development.
- The accelerated PDAC phenotype was associated with early upregulation of TNFA and IL6.
- Increased immune cell recruitment was observed in the pancreas of Mir34a-deficient mice.
Conclusions:
- Mir34a acts as a suppressor of PDAC development.
- Mir34a restrains PDAC progression by modulating the pancreatic tumor immune microenvironment.
- Restoration of Mir34a presents a potential therapeutic strategy for PDAC inhibition.
